Difference between revisions of "Tagraxofusp (Elzonris)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Diphtheria toxin conjugated to interleukin 3 | Diphtheria toxin conjugated to interleukin 3 | ||
| − | =Preliminary studies= | + | ==Preliminary studies== |
# Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24859366 PubMed] | # Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. [http://www.bloodjournal.org/content/124/3/385.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24859366 PubMed] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | |||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:Blastic plasmacytoid dendritic cell neoplasm medications]] | [[Category:Blastic plasmacytoid dendritic cell neoplasm medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 19:04, 18 December 2018
Mechanism of action
Diphtheria toxin conjugated to interleukin 3
Preliminary studies
- Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed